



Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

S. Degryse^{1,2} · C. E. de Bock^{1,2} · S. Demeyer^{1,2} · I. Govaerts^{1,2} · S. Bornschein^{1,2} · D. Verbeke^{1,2} · K. Jacobs^{1,2} · S. Binos³ · D. A. Skerrett-Byrne^{4,5} · H. C. Murray^{4,5} · N. M. Verrills^{4,5} · P. Van Vlierberghe^{6,7} · J. Cools^{1,2} · M. D. Dun^{4,5}

Published online: 19 September 2018
© The Author(s) 2018

Correction to: *Leukemia* ; <https://doi.org/10.1038/leu.2017.276>; published online: 30 August 2017

Following the publication of this article the authors noted that data describing precisely where phosphorylation sites in proteins modulated following JAK1 or JAK3 inhibition in

mutant T-ALL samples was not clearly annotated. Therefore an additional sheet has been added to Supplementary Table 2.

The authors wish to apologize for any inconvenience caused.

These authors contributed equally: S. Degryse, C.E. de Bock.

✉ J. Cools
jan.cools@kuleuven.vib.be

✉ M. D. Dun
matt.dun@newcastle.edu.au

¹ VIB Center for Cancer Biology, Leuven, Belgium

² KU Leuven Center for Human Genetics, Leuven, Belgium

³ Thermo Fisher Scientific, Scoresby, VIC, Australia

⁴ Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia

⁵ Cancer Research Program, School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, New South Wales, Australia

⁶ Department of Pediatrics and Genetics, Center for Medical Genetics, Ghent University, Ghent, Belgium

⁷ Cancer Research Institute Ghent, Ghent, Belgium